FDA Approves Citius Pharmaceuticals' Lymphir (Denileukin Diftitox-cxdl) For R/R Cutaneous T-cell Lymphoma After At Least One Prior Systemic Therapy. This Is The First Indication For Lymphir And The First FDA-approved Product For Citius Pharma
Portfolio Pulse from Benzinga Newsdesk
The FDA has approved Citius Pharmaceuticals' Lymphir (Denileukin Diftitox-cxdl) for the treatment of relapsed or refractory cutaneous T-cell lymphoma after at least one prior systemic therapy. This marks the first indication for Lymphir and the first FDA-approved product for Citius Pharmaceuticals.
August 08, 2024 | 11:50 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
The FDA approval of Lymphir for relapsed or refractory cutaneous T-cell lymphoma is a significant milestone for Citius Pharmaceuticals, marking its first FDA-approved product.
The FDA approval of Lymphir is a major regulatory milestone for Citius Pharmaceuticals, likely to boost investor confidence and positively impact the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100